Nautilus Biotechnolgy, Inc.
NAUT
Rank in Stocks
#14756
Nautilus Biotechnology, Inc., a development stage life sciences company,... Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Share Price
$2.38
Last synced: 2026-11-09
Market Cap
$303.15M
Change (1 day)
6.73%
Change (1 year)
37.57%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Nautilus Biotechnolgy, Inc. (NAUT)
Category
Healthcare
EPS for Nautilus Biotechnolgy, Inc. (NAUT)
EPS as of September 2026 TTM: $-0.46
According to Nautilus Biotechnolgy, Inc.'s latest financial reports, its current EPS (TTM) is $-0.46. At the end of 2025 the company had an EPS of $-0.47, an increase over its 2024 EPS of $-0.56.
EPS history for Nautilus Biotechnolgy, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.46 | -2.13% |
| 2025 | $-0.47 | -16.07% |
| 2024 | $-0.56 | 9.80% |
| 2023 | $-0.51 | 10.87% |
| 2022 | $-0.46 | -23.33% |
| 2021 | $-0.60 | 27.66% |
| 2020 | $-0.47 | -70.44% |
| 2019 | $-1.59 | -101.82% |
| 2018 | $87.18 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,504.35% |
US
|
|
| $-7.07 | 1,436.96% |
US
|
|
| $-5.29 | 1,050.00% |
AU
|
|
| $12.88 | -2,900.02% |
BE
|
|
| $21.56 | -4,786.96% |
NL
|
Questions about Nautilus Biotechnolgy, Inc.'s earnings per share (EPS)
What is Nautilus Biotechnolgy, Inc.'s earnings per share (EPS)?
Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) over the last twelve months is $-0.46, as of Sep 2026.
What was Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) in 2025?
In 2025, Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) was $-0.47, compared with $-0.56 in 2024.
How has Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) was highest in 2022 ($-0.46) and lowest in 2021 ($-0.60).
How does Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) compare with similar companies?
Nautilus Biotechnolgy, Inc.'s earnings per share (EPS) ($-0.46) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.